Compare Divis Laboratories with Biocon - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs BIOCON - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES BIOCON DIVIS LABORATORIES/
BIOCON
 
P/E (TTM) x 51.5 31.4 164.3% View Chart
P/BV x 11.9 4.0 298.7% View Chart
Dividend Yield % 0.5 0.2 207.9%  

Financials

 DIVIS LABORATORIES   BIOCON
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
BIOCON
Mar-19
DIVIS LABORATORIES/
BIOCON
5-Yr Chart
Click to enlarge
High Rs1,639707 231.8%   
Low Rs1,115554 201.3%   
Sales per share (Unadj.) Rs186.391.9 202.7%  
Earnings per share (Unadj.) Rs51.016.7 304.9%  
Cash flow per share (Unadj.) Rs57.324.2 237.1%  
Dividends per share (Unadj.) Rs16.001.00 1,600.0%  
Dividend yield (eoy) %1.20.2 732.6%  
Book value per share (Unadj.) Rs261.8101.6 257.6%  
Shares outstanding (eoy) m265.47600.00 44.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.46.9 107.7%   
Avg P/E ratio x27.037.7 71.6%  
P/CF ratio (eoy) x24.026.1 92.1%  
Price / Book Value ratio x5.36.2 84.8%  
Dividend payout %31.46.0 524.7%   
Avg Mkt Cap Rs m365,592378,330 96.6%   
No. of employees `00011.86.1 193.2%   
Total wages/salary Rs m5,42311,653 46.5%   
Avg. sales/employee Rs Th4,175.18,994.3 46.4%   
Avg. wages/employee Rs Th457.71,900.7 24.1%   
Avg. net profit/employee Rs Th1,141.81,635.3 69.8%   
INCOME DATA
Net Sales Rs m49,46355,144 89.7%  
Other income Rs m1,5561,444 107.8%   
Total revenues Rs m51,01956,588 90.2%   
Gross profit Rs m18,71815,883 117.9%  
Depreciation Rs m1,6894,478 37.7%   
Interest Rs m35709 4.9%   
Profit before tax Rs m18,55112,140 152.8%   
Minority Interest Rs m09 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,0232,123 236.6%   
Profit after tax Rs m13,52710,026 134.9%  
Gross profit margin %37.828.8 131.4%  
Effective tax rate %27.117.5 154.8%   
Net profit margin %27.318.2 150.4%  
BALANCE SHEET DATA
Current assets Rs m46,50148,228 96.4%   
Current liabilities Rs m8,46830,376 27.9%   
Net working cap to sales %76.932.4 237.5%  
Current ratio x5.51.6 345.9%  
Inventory Days Days13168 191.5%  
Debtors Days Days8686 100.4%  
Net fixed assets Rs m25,79764,130 40.2%   
Share capital Rs m5313,000 17.7%   
"Free" reserves Rs m68,96257,980 118.9%   
Net worth Rs m69,49360,980 114.0%   
Long term debt Rs m015,766 0.0%   
Total assets Rs m80,383121,924 65.9%  
Interest coverage x531.018.1 2,930.1%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.5 136.1%   
Return on assets %16.98.8 191.6%  
Return on equity %19.516.4 118.4%  
Return on capital %26.716.8 159.6%  
Exports to sales %028.1 0.0%   
Imports to sales %24.618.9 130.7%   
Exports (fob) Rs mNA15,506 0.0%   
Imports (cif) Rs m12,18710,399 117.2%   
Fx inflow Rs m41,23815,506 265.9%   
Fx outflow Rs m12,40510,399 119.3%   
Net fx Rs m28,8335,107 564.6%   
CASH FLOW
From Operations Rs m9,54311,546 82.7%  
From Investments Rs m-6,854-7,138 96.0%  
From Financial Activity Rs m-2,459-2,417 101.8%  
Net Cashflow Rs m2302,103 10.9%  

Share Holding

Indian Promoters % 52.0 40.4 128.7%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 11.8 8.4 140.5%  
FIIs % 19.0 10.7 177.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 19.9 86.4%  
Shareholders   31,796 109,995 28.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  ORCHID PHARMA  SANOFI INDIA  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 173 Points Lower; Capital Goods and FMCG Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended marginally lower.

Related Views on News

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

My View on ITC(Fast Profits Daily)

Oct 23, 2020

What do the charts say about ITC?

PSU Banks Will Move Up Again(Profit Hunter)

Oct 27, 2020

My charts tell me PSU banks are set for a rebound.

One of the Best Investment Opportunities in the Market Right Now(Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

Why India's Drone Revolution is a 4x Profit Opportunity(Profit Hunter)

Oct 16, 2020

My research on India's leading defence companies brought me to one major player in drone manufacturing.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Oct 29, 2020 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS